Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Oct 28, 2020

by Zacks Equity Research

Companies In The News Are: PFE, LLY, MMM, SHW.

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FTCS

Exelixis' (EXEL) Applications for Cabometyx-Opdivo Combo Accepted (Revised)

by Zacks Equity Research

Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.

Lilly (LLY) Q3 Earnings & Revenues Lag Estimates, Stock Down

by Zacks Equity Research

Eli Lilly (LLY) misses on both earnings and sales for the third quarter. The company reiterates its revenue guidance for 2020.

The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen

Pfizer (PFE) Q3 Earnings Top, Sales Miss, View Narrowed

by Zacks Equity Research

Pfizer (PFE) beats estimates for earnings while missing the same for sales. It narrows its financial outlook for the year.

Pfizer (PFE) Q3 Earnings Beat Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 2.86% and -0.83%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Pfizer's (PFE) Oncology Drugs Drive Its Q3 Earnings?

by Zacks Equity Research

In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the third quarter, while in non-oncology, Eliquis alliance revenues are likely to have supported the top line.

Sweta Killa headshot

Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

by Sweta Killa

The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

Novartis (NVS) Gets Orphan Drug Tag for Huntington's Disease Drug

by Zacks Equity Research

Novartis (NVS) gets orphan drug designation for branaplam (LMI070) in Huntington's disease.

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

by Zacks Equity Research

Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.

AstraZeneca (AZN), J&J (JNJ) Coronavirus Trials May Resume Soon

by Zacks Equity Research

Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.

Sweta Killa headshot

Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

by Sweta Killa

The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals

by Zacks Equity Research

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.

Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline

by Zacks Equity Research

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC

by Zacks Equity Research

Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.

Aptinyx (APTX) Surges on Promising Stress Disorder Study Data

by Zacks Equity Research

Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.

Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.

Pfizer (PFE) Stock Moves -0.4%: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed at $37.80 in the latest trading session, marking a -0.4% move from the prior day.

Sweta Killa headshot

Weekly ETF Roundup: Broad U.S. Equity Tops, Biotech Flops

by Sweta Killa

ETFs overall gathered about $18.5 billion capital last week, bringing year-to-date inflows of $352.6 billion, ahead of the $211.7 billion seen at this same time a year ago.

Stock Market News for Oct 19, 2020

by Zacks Equity Research

The Dow and the S&P 500 closed higher on Friday, lifted by upbeat retail sales data and improvement in consumer sentiment.

Lilly to Acquire Private Biotech for Boosting Pain Portfolio

by Zacks Equity Research

Lilly (LLY) inks a deal to acquire Disarm Therapeutics for an upfront payment of $135 million to strengthen its pain and neurological diseases portfolio.

Retail and Core Retail Sales Jump in September

by Zacks Equity Research

Retail and Core Retail Sales Jump in September.

Mark Vickery headshot

Retail Sales +1.9%, Industrial Production -0.6%

by Mark Vickery

While September Retail Sales were ahead of expectations, Industrial Production last month was decidedly not.

The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, Target, Prudential Financial and Seagate Technology

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, Target, Prudential Financial and Seagate Technology